{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:08:16Z","timestamp":1792724896748,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T00:00:00Z","timestamp":1356048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s40263-012-0026-x","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T08:29:04Z","timestamp":1355992144000},"page":"67-80","source":"Crossref","is-referenced-by-count":35,"title":["Lurasidone"],"prefix":"10.1007","volume":"27","author":[{"given":"Mark","family":"Sanford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"issue":"9690","key":"26_CR1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J Os van","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635\u201345.","journal-title":"Lancet"},{"issue":"9","key":"26_CR2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4088\/JCP.10r06264yel","volume":"71","author":"JM Kane","year":"2010","unstructured":"Kane JM, Correll CU. Past and present progress in the pharmacological treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"26_CR3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/0023210-200822120-00007","volume":"22","author":"RD Jindal","year":"2008","unstructured":"Jindal RD, Keshavan MS. Classifying antipsychotic agents: need for new terminology. CNS Drugs. 2008;22(12):1047\u201359.","journal-title":"CNS Drugs"},{"issue":"2","key":"26_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/cn1001123","volume":"2","author":"CR Hopkins","year":"2011","unstructured":"Hopkins CR. ACS chemical neuroscience molecule spotlight on Latuda (lurasidone; SM-13,496). ACS Chem Neurosci. 2011;2(2):58\u20139.","journal-title":"ACS Chem Neurosci"},{"key":"26_CR5","unstructured":"Sunovion Pharmaceuticals Inc. Latuda (lurasidone hydrochloride) tablets, for oral use: US prescribing information. 2012. http:\/\/latuda.com\/LatudaPrescribingInformation.pdf . Accessed 2012 Sep 12."},{"issue":"1","key":"26_CR6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171\u201381.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"26_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145711000150","volume":"15","author":"F Fumagalli","year":"2012","unstructured":"Fumagalli F, Calabrese F, Luoni A, et al. Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. Int J Neuropsychopharmcol. 2012;15(2):235\u201346.","journal-title":"Int J Neuropsychopharmcol"},{"issue":"2","key":"26_CR8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/mol.111.076141","volume":"81","author":"EY Yuen","year":"2012","unstructured":"Yuen EY, Li X, Wei J, et al. The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses. Mol Pharmacol. 2012;81(2):113\u20139.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"26_CR9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","volume":"186","author":"T Enomoto","year":"2008","unstructured":"Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res. 2008;186(2):197\u2013207.","journal-title":"Behav Brain Res"},{"key":"26_CR10","unstructured":"Enomoto T. Effects of the novel antipsychotic lurasidone on prefrontal cognitive functioning in rats [abstract no. 646.24\/V36]. 39th Annual Meeting of the Society for Neuroscience, Chicago, IL; 2009."},{"key":"26_CR11","first-page":"94","volume":"13","author":"K Ikeda","year":"2010","unstructured":"Ikeda K, Fukuoka T, Ikejiri M, et al. Cognitive enhancing effects of lurasidone in non-human primates: object retrieval with detours, a test of executive function [abstract]. Int J Neuropsychopharmcol. 2010;13:94\u20135.","journal-title":"Int J Neuropsychopharmcol"},{"key":"26_CR12","first-page":"S436","volume":"36","author":"M Horiguchi","year":"2011","unstructured":"Horiguchi M, Hannaway KE, Adelekun AE, et al. Subchronic treatment with lurasidone has both preventive and enduring reversal effects on the phencyclidine (PCP)-induced deficit in novel object recognition (NOR) in rats [abstract]. Neuropsychopharmacology. 2011;36:S436.","journal-title":"Neuropsychopharmacology"},{"key":"26_CR13","first-page":"S173","volume":"36","author":"SG Potkin","year":"2011","unstructured":"Potkin SG, Keator DB, Preda A, et al. D2 receptor occupancy measured with 18F-fallypride following lurasidone treatment in schizophrenia patients [abstract]. Neuropsychopharmacology. 2011;36:S173.","journal-title":"Neuropsychopharmacology"},{"issue":"2\u20133","key":"26_CR14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.schres.2010.02.669","volume":"117","author":"PD Harvey","year":"2010","unstructured":"Harvey PD, Murasaki M, Cucchiaro J, et al. A three arm dose finding study of lurasidone: efficacy and tolerability data [abstract]. Schizophr Res. 2010;117(2\u20133):374\u20135.","journal-title":"Schizophr Res"},{"key":"26_CR15","first-page":"S32","volume":"89","author":"Y Chiu","year":"2011","unstructured":"Chiu Y, Gu K, Poola N, et al. Effect of hepatic impairment on the pharmacokinetics of lurasidone [abstract]. Clin Pharmacol Ther. 2011;89:S32.","journal-title":"Clin Pharmacol Ther"},{"key":"26_CR16","first-page":"S395","volume":"35","author":"S Preskorn","year":"2010","unstructured":"Preskorn S, Chiu YY, Sarubbi D, et al. Lurasidone pharmacokinetics: assessment of potential for drug-drug interactions [abstract]. Neuropsychopharmacology. 2010;35:S395.","journal-title":"Neuropsychopharmacology"},{"key":"26_CR17","doi-asserted-by":"crossref","unstructured":"Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week placebo-controlled study. Psychopharmacology (Berl). 2012 February 19 (Epub).","DOI":"10.1007\/s00213-012-2838-2"},{"key":"26_CR18","unstructured":"Centre for Drug Evaluation and Research. Medical review lurasidone 2010. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/200603Orig1s000MedR.pdf . Accessed 2012 Sep 12."},{"issue":"6","key":"26_CR19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829\u201336.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"26_CR20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957\u201367.","journal-title":"Am J Psychiatry"},{"key":"26_CR21","first-page":"S313","volume":"35","author":"A Loebel","year":"2010","unstructured":"Loebel A, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, pearl 3 trial [abstract]. Neuropsychopharmacology. 2010;35:S313\u20134.","journal-title":"Neuropsychopharmacology"},{"key":"26_CR22","unstructured":"Dainippon Sumitomo Pharma Co Ltd. Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia [media release]. 2011. http:\/\/www.ds-pharma.com ."},{"key":"26_CR23","unstructured":"Pikalov A, Cucchiaro J, Sarma K, et al. Lurasidone in the acute treatment of schizophrenia: results of the double-blind placebo- and quetiapine XR-controlled 6-week study of lurasidone in adult patients with schizophrenia [abstract no. 225]. Poster presented at the 26th Annual US Psychiatric and Mental Health Congress. 2011 Nov 7-10, Las Vegas, NEV."},{"key":"26_CR24","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1038\/npp.2010.29","volume":"35","author":"S Stahl","year":"2010","unstructured":"Stahl S, Cucchiaro J, Simonelli D, et al. Long-term safety and tolerability of lurasidone in subjects with schizophrenia: results of a 6-month, open-label study [abstract]. Neuropsychopharmacology. 2010;35:S316\u20137.","journal-title":"Neuropsychopharmacology"},{"key":"26_CR25","first-page":"S101","volume":"36","author":"A Loebel","year":"2011","unstructured":"Loebel A, Cucchiaro J, Xu J, et al. Relapse prevention with lurasidone vs. quetiapine XR in chronic schizophrenia: results of a 12-month, double-blind study. Neuropsychopharmacology. 2011;36:S101.","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"26_CR26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","volume":"127","author":"PD Harvey","year":"2011","unstructured":"Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127(1\u20133):188\u201394.","journal-title":"Schizophr Res"},{"issue":"2","key":"26_CR27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","volume":"6","author":"L Citrome","year":"2012","unstructured":"Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6(2):76\u201385.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"26_CR28","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1038\/npp.2010.223","volume":"36","author":"P Harvey","year":"2011","unstructured":"Harvey P, Cucchiaro J, Pikalov A, et al. Cognitive performance in patients with schizophrenia treated with lurasidone: results from a placebo- and active-controlled acute phase study followed by a 6\u00a0month double-blind extension [abstract]. Neuropsychopharmacology. 2011;36:S169\u201370.","journal-title":"Neuropsychopharmacology"},{"key":"26_CR29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/schbul\/sbp048","volume":"37","author":"JW Newcomer","year":"2011","unstructured":"Newcomer JW, Siu C, Pikalov A, et al. Impact of lurasidone and olanzapine on framingham 10-year coronary heart disease risk estimate in schizophrenia [abstract]. Schizophr Bull. 2011;37:316.","journal-title":"Schizophr Bull"},{"issue":"3","key":"26_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","volume":"27","author":"L Citrome","year":"2012","unstructured":"Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165\u201376.","journal-title":"Int Clin Psychopharmacol"},{"key":"26_CR31","unstructured":"Sunovien. PEARL Schizophrenia Maintenance study (NCT01435928) [online]. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01435928 . Accessed Oct 9 2012."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0026-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-012-0026-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0026-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T06:10:39Z","timestamp":1562479839000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-012-0026-x"}},"subtitle":["In the Treatment of Schizophrenia"],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1007\/s40263-012-0026-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}